ArticleFrontiers in endocrinology2025
Age rather than diabetes duration predicts the severity of sensory neuropathy in type 2 diabetes mellitus.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: In patients with type 2 diabetes, factors beyond hyperglycemia may contribute to the development of sensory neuropathy. This study aimed to determine whether diabetes duration was the strongest predictor of prevalent sensory neuropathy and to compare the diagnostic performance of commonly used clinical screening methods. Materials and methods: A total of 711 patients with type 2 diabetes from the Budapest metropolitan area were assessed between 2016 and 2022 using routine sensory neuropathy screening tests (128-Hz tuning fork and 10-g monofilament). A brief standardized questionnaire was also administered to support neuropathy detection. Independent predictors of sensory neuropathy were identified using binary logistic regression models and interrater agreement between diagnostic methods was assessed with Cohen's kappa. Results: Agreement between diagnostic methods was only moderate (Cohen's kappa: 0.3-0.4). In the final adjusted models, age emerged as the only independent predictor of neuropathy detected by tuning fork testing (OR 1.04; 95% CI 1.02-1.06), whereas for the monofilament test, self-reported neuropathic symptoms remained independently associated. Consistent with this, positive responses to standardized symptom questions correlated with both diagnostic tests, supporting their clinical validity. Conclusion: The overlap between routinely applied clinical methods for detecting sensory neuropathy is limited. Our findings suggest that, in an aging population with type 2 diabetes, peripheral nerve damage identified by standard screening tools is more strongly associated with age than with diabetes duration when assessed by commonly used bedside screening tools. Prospective studies are warranted to better differentiate diabetic neuropathy from age-related nerve dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.